Introduction: The recently developed Myasthenia Gravis Impairment Index (MGII) is a promising measure as it has less floor effects and a higher relative efficiency in its responsiveness to treatment effect compared to other MG measures. This study aimed at validating the MGII in a Dutch cohort of MG patients and analyzing the sensitivity of MGII compared to MG-ADL for changes in generalized weakness. Methods: We analyzed (generalized items of; -gen) MGII, quantitative myasthenia gravis (QMG), Myasthenia Gravis Activities of Daily Living (MG-ADL), EQ-5D visual analog, Myasthenia Gravis Composite (MGC) and ACTIVLIM (an ADL questionnaire focusing on generalized weakness) scores in a prospective cohort of 99 MG patients. We investigated correlations between MGII and other outcome measures. We used a generalized linear model to assess whether MGIIgen had an additional sensitivity on top of MG-ADLgen for changes (Δ) in QMGgen in individual patients. Results: MGII had a lower floor effect (4%) compared to QMG (6%), MG-ADL (11%) and MGC (16%). MGII correlated well with QMG (r = 0.68), MG-ADL (r = 0.83) and MGC (r = 0.74). As expected, the correlations with EQ visual analog and ACTIVLIM were lower (r = – 0.57 and – 0.48). ΔMGIIgen had an additional value on top of ΔMG-ADLgen in the prediction of ΔQMGgen (B = 0.54, p = 0.01). Discussion: The MGII score was cross-culturally validated in a Dutch cohort of MG patients. MGII had a higher sensitivity for generalized weakness than MG-ADL.
[1]
E. V. van Zwet,et al.
Sensitivity of MG‐ADL for generalized weakness in myasthenia gravis
,
2018,
European journal of neurology.
[2]
J. Verschuuren,et al.
Distinct representation of muscle weakness in QMG and MG-ADL
,
2018,
The Lancet Neurology.
[3]
V. Bril,et al.
The utility of a single simple question in the evaluation of patients with myasthenia gravis
,
2018,
Muscle & nerve.
[4]
A. Davis,et al.
Myasthenia Gravis Impairment Index
,
2017,
Neurology.
[5]
A. Davis,et al.
Development and validation of the Myasthenia Gravis Impairment Index
,
2016,
Neurology.
[6]
R. Lewis.
Myasthenia gravis: New therapeutic approaches based on pathophysiology
,
2013,
Journal of the Neurological Sciences.
[7]
A. Davis,et al.
Performance of individual items of the quantitative myasthenia gravis score
,
2013,
Neuromuscular Disorders.
[8]
D. Sanders,et al.
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
,
2009,
The Lancet Neurology.
[9]
J. Corbett.
Treatment of Ocular Symptoms in Myasthenia Gravis
,
2009
.
[10]
M. Benatar,et al.
Treatment of ocular symptoms in myasthenia gravis
,
2008,
Neurology.
[11]
A. Sperber.
Translation and validation of study instruments for cross-cultural research.
,
2004,
Gastroenterology.